Eli Lilly and Alchemab Therapeutics hope to discover novel therapeutic candidates to treat amyotrophic lateral sclerosis (ALS) as part of a new research collaboration.  Alchemab’s technology platform uses patient samples from individuals with unusually slow rates of disease progression to identify antibodies associated with resilience.   The company believes these antibodies, which are not found in […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!